The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Progenics (Inst)
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
 
Evan Y. Yu
Research Funding - Progenics (Inst)
 
David Laidley
Research Funding - Progenics (Inst)
 
Frederic Pouliot
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Genzyme; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Genzyme; Janssen; Pfizer; Progenics; Sanofi
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Janssen; Sanofi
Patents, Royalties, Other Intellectual Property - Transcriptional system and uses therof for single cell detection
Other Relationship - Merck; Progenics
 
Stephan Probst
Stock and Other Ownership Interests - Endocyte; Johnson & Johnson; Pfizer; Progenics
Honoraria - Advanced Accelerator Applications; Bayer; Isologic
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer
Research Funding - Bayer (Inst); Progenics (Inst)
Travel, Accommodations, Expenses - Advanced Accelerator Applications; Bayer
 
Robert Sabbagh
Research Funding - Progenics (Inst)
 
Giuseppe Esposito
Research Funding - Progenics (Inst)
 
Fred Saad
No Relationships to Disclose
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbvie; Cardinal Health; GlaxoSmithKline; Lilly; PSMA Therapeutics; United Health Group; Varian Medical Systems
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Endocyte; Johnson & Johnson; Myovant Sciences; Myriad Genetics; Novartis; Novartis; Noxopharm; Pfizer; Progenics; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); Innocrin Pharma (Inst); InVitae (Inst); Johnson & Johnson (Inst); Merck (Inst); Sanofi (Inst); SOTIO
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi